Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > The misuse of “noninferiority” in presenting trials is often misleading
  • News

The misuse of “noninferiority” in presenting trials is often misleading

  • 11 May 2020
  • Elena Riboldi
The misuse of “noninferiority” in presenting trials is often misleading
Total
0
Shares
0
0
0
0
0

When researchers have the opportunity to present their trials at medical meetings, they tend to use not-negative conclusions to discuss formally negative results. A research published in JAMA Oncology by a group of Italian oncologists from the University of Turin and the National Cancer Institute – “Fondazione G. Pascale”, Naples, shows that one third of oral presentations about phase 3 trials that failed to demonstrate the efficacy of an experimental treatment had not-negative conclusions. Of note, those abstracts were presented at two of the most important international oncology meetings, the ASCO and the ESMO annual meetings.

“We believe that more attention should be paid to the statements included in the conclusions of oral presentations at meetings, and the discussants’ role is crucial. When the primary end point is not met, the word negative should be explicitly used”, Massimo Di Maio and Francesco Perrone, supervisors of the study, wrote. Meetings are a privileged occasion to reach not only the scientific community, but also the general public, through the lay press and the media, and the risk of sending out messages that are not completely justified by data is real.

Authors selected 208 oral communications about phase 3 clinical studies presented at the ASCO and the ESMO annual meetings in the past three years. They identified 91 negative trials, i.e. studies where the primary endpoint of efficacy was not met. Conclusions were considered to be not-negative when, more or less explicitly, authors consider the possibility of using the experimental treatment in that setting, without making clear statements about the study negativity.

Of the 91 negative studies, 26 (29%) had a not-negative conclusion. The proportion of negative studies with not-negative conclusions was 22% in 2017, 13% in 2018, and 47% in 2019. Interestingly, the proportion was similar in nonprofit and for-profit studies (30% and 26%, respectively). In 7 cases (27%), authors interpreted post hoc the study as a noninferiority design.

“When a trial is designed to test the superiority of an experimental treatment, post hoc interpretation of noninferiority is methodologically debatable” the authors remarked. “The noninferiority hypothesis should be prospectively planned, with a clear definition of the margin acceptable to define noninferiority.”

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • clinical trials
  • noninferiority
  • not negative
  • oral presentations
  • resultsù
Elena Riboldi

Previous Article
  • Voices

Delivering cancer care during the pandemic in Europe’s most overstretched health system

  • 10 May 2020
  • Geta Roman
View Post
Next Article
  • News

Hormone therapy for prostate cancer may shield from COVID-19

  • 18 May 2020
  • Elena Riboldi
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Yeva Margaryan
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Yeva Margaryan
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.